Dexcom (DXCM) FY2016 results: revenue $573 million, up 42.6% on the year
Dexcom Inc. (DXCM) reported revenue of $573 million for fiscal 2016, the year ended 31 December 2016, up 42.6% on the year before. Net income was -$66 million, and diluted earnings per share $-0.78. The figures are the company's own, from the 10-K it filed with the SEC on 21 February 2019.
Revenue
$573 million
+42.6% on the year
FY2009FY2016
Operating margin
-11.1%
-14.2% a year earlier
FY2009FY2016
Net income
-$66 million
FY2009FY2016
Diluted EPS
-$0.78
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
573
402
259
+42.6%
Cost of revenue
195
124
82.9
+57.7%
Gross profit
378
278
176
+35.9%
Gross margin
66.0%
69.3%
68.0%
Research and development
156
138
69.4
+13.5%
Selling, general and administrative
286
198
128
+44.5%
Operating income
-63.9
-57.1
-21.5
Operating margin
-11.1%
-14.2%
-8.3%
Interest expense
0.7
0.4
0.8
+75.0%
Pre-tax income
-64.9
-57.5
-22.3
Income tax
0.7
0.1
0.1
+600.0%
Net income
-65.6
-57.6
-22.4
Net margin
-11.4%
-14.3%
-8.6%
Diluted EPS
-$0.78
-$0.72
-$0.30
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
56.2
49.0
23.6
+14.7%
Capital expenditure
55.7
33.3
16.2
+67.3%
Free cash flow
0.5
15.7
7.4
-96.8%
Free cash flow margin
0.1%
3.9%
2.9%
Cash from investing
-55.9
-51.5
-16.8
Cash from financing
8.1
16.8
21.8
-51.8%
Depreciation and amortisation
15.0
10.8
8.4
+38.9%
Share-based compensation
111
82.7
50.0
+34.0%
Buybacks
0.0
n/a
n/a
Shares outstanding at period end
85m
82m
77m
+3.5%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
284
221
140
+28.3%
Debt
0.0
2.3
4.6
Other liabilities
119
68.5
39.8
+73.7%
Total liabilities and equity
403
292
185
+37.9%
Fixed assets
109
54.7
31.2
+100.0%
Goodwill
11.3
3.7
3.2
+205.4%
Intangible assets
0.2
2.2
2.7
-90.9%
Investments
35.1
29.1
11.8
+20.6%
Cash and equivalents
94.5
86.1
71.8
+9.8%
Receivables
102
74.1
42.4
+37.2%
Inventory
45.4
35.2
16.0
+29.0%
Other assets
5.2
6.9
5.5
-24.6%
Total assets
403
292
185
+37.9%
10-K for the year ended 31 December 2016, filed 21 February 2019: the filing.